CG Oncology (CGON) stock

Bladder cancer immunotherapy , market cap $5.7B

Immunotherapy for bladder cancer patients

Worth $5.7B

$72.64

-2.81%

As of Tuesday's close · Live for Pro members at the open

Quality Score

Below Average

In its industry

#81of 281

Biotech

Checks firing

3of 14

Trending up

From 52-week high

-10.3%

under its best in a year

CGON's Quality Score fell 2 points on Tue, Nov 10, to 4. Its 6-month gain fell to 1%, under 25.5%.

Follow CGON's trial news. Pro members can get an alert when CG Oncology files news, and see its trials, share raises, and its CEO's filings.

Get an alert when CGON files news on its trialsSee it live, free until Thursday morning. No account. No card. Then keep going with a free account.

We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.

NextQ4 2026“BLA completion for BCG-unresponsive NMIBC anticipated Q4 2026”Filing with regulators · SEC filing · Nov 6

Why CGON rose on Nov 6

Up 17% on Nov 6 while the S&P 500 rose 0.3%.

It reported quarterly revenue of $1.6M that day.

Sources: Price history, Nov 6, 2026; SEC filing, Nov 6, 2026; Company release (8-K), Nov 6, 2026

1 more reason, free with an account →The other side, how the business stands, the timeline, and its peers, for Pro members.

Key facts on CGON

Key facts on CGON
Holding it back	A $237M loss wider than $151M a year earlier
Latest filing	8-K, Nov 6 Reported its quarterly results

1 more reason behind CGON's 4, free with an account →4 more reasons behind CGON's 4, for Pro members.

CGON in the news

Fri Nov 6CG Oncology reported $1.6 million of quarterly revenue SEC, 8:30 AM ET CGON closed +17.3% that day.

CGON catalysts

Coming up

After its last 4 reports it closed +6.5% on average, higher 4 of 4 times.

What's next for CGON, and how long its cash lasts

Next step the company has named

Q4 2026“BLA completion for BCG-unresponsive NMIBC anticipated Q4 2026”Filing with regulators · SEC filing · Nov 6

What it means: a filing asks regulators to approve a drug for sale. Once it is complete and accepted, the FDA sets a decision date, and we show it here.

A trial underway: Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBTPhase 3 · Active · 367 people · main data estimated Nov 2026 · NCT06111235

2 more trials, 30 filings, for Pro members.

Cash runway

The company says its cash lasts through 2029 (8-K, Nov 6).

That is the company's estimate. Our arithmetic on its latest balance sheet reads differently, so we show its words, not ours.

For Pro members: the cash on hand, the cash used each quarter, and the math.

Dilution on the horizon

Shelf registration (S-3ASR, filed Mar 28, 2025)
At-the-market share sales program (S-3ASR, filed Mar 28, 2025)

For Pro members: 2 raises and their amounts, and the share count against a year ago.

Insiders

Director Leonard E. Post sold 1,000 shares on Oct 15, under a planned sale. 12 more insider trades this year.

From Form 4: open-market buys and sales only.

Get an alert when Arthur Kuan buys or sells

For Pro members: every trade, and Arthur Kuan’s 11 filings and quotes.

Get an alert when CGON files news on its trialsA free account. No card.

See every upcoming FDA date →

FDA dates in the next 60 days

Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.

DateStockDrug

In 12 daysFDA decisionIn 12 days · FDA decisionCAPRCapricor TherapeuticsDeramiocelCAPRCapricor Therapeutics · $500MDeramiocelFDA decision due (PDUFA)
In 12 daysFDA decisionIn 12 days · FDA decisionSVRASavaraMolgramostimSVRASavara · $900MMolgramostimFDA decision due (PDUFA)
In 42 daysFDA decisionIn 42 days · FDA decisionMLYSMineralys TherapeuticsLorundrostatMLYSMineralys Therapeutics · $1.3BLorundrostatFDA decision due (PDUFA)

14 more FDA dates and 103 trial data dates in the next 60 days, each on the FDA calendar. Pro members see whether each company's cash lasts past its date, with an optional alert before it. See all 151 dates, ranked →

Why CGON scores 4

Below Averagefor quality, not price, 3 of 14 chart checks firingWhat the Quality Score means

+3Chart checks 3 of 14 firing right now, one point each
+3Long-term trend above a rising 200-⁠day average, near its 52-⁠week high

Profit subtractsRead on the last four quarters against the four before, or the last full year where no quarters are filed.
Growth addsSales and margins against a year earlier: up to +3 for fast growth and widening margins, down to -2 when both shrink.
Dilution subtractsNew shares over the year: -1 at 10% more, -2 at 25% more.
Volatility subtractsA daily range of 5% or more with nothing behind it (no profit or cash flow, sales shrinking, or 10% more shares outstanding with no free cash flow): -1, or -2 from 8%.
Cash flow subtracts-1 when free cash flow over the last four quarters is negative.

No effect today: Run-up, Size, Persistence, and News.

What every line is worth, and the reason behind it, on CGON and every other stock.Get in free →

Price, score, chart checks, and the industry rank are from a snapshot taken at 11:13 PM ET, at least 15 minutes behind. How we rank stocks.

Tested. Our top-scored stocks returned 2.2x the average stock over the next month. Reconstructed after the fact; recorded live since Sep 9, 2026. How we tested it

Alert me when CGON's Quality Score turns up

A free account. No card.

How CGON ranks in Biotech

CGON is #81 of 281 by Quality Score.

How CGON ranks in Biotech
Rank	Stock	Checks	Quality Score
1	ONCBeOne Medicines	8/14	24
2	VCELVericel	8/14	22
3	ETONEton Pharmaceutcials	9/14	20
	CAPRCapricor Therapeutics		Open for its score
	CGEMCullinan Therapeutics		Open for its score
	CLDXCelldex Therapeutics		Open for its score
	CLYMClimb Bio		Open for its score
81	CGONCG Oncology	3/14	4

Share count against a year before: CGON +16%, EXEL -8.1%, IOVA +25%, DNLI +9.3%.

When does CGON report earnings, and what happens after?

Expected to report Fri Feb 26, before the open (in 108 days).

What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.

What CGON reported on Nov 6, 2026

The quarter

Sales of $1.6M, 4% less than a year ago.

“The increase was primarily due to an increase in clinical trial expenses, including CMC costs, and an increase in compensation costs due to increased headcount.”

The quarter that ended Sep 30, from the company's press release

The press release The filing on EDGAR

Where the sales came from

CGON's results filing gives no sales by line in a table we read.

The outlook

No outlook figures read from this release.

In the company's words

“The decrease was primarily due to a decrease in professional and consultant fees, partially offset by an increase in personnel-related expenses, including compensation costs from increased headcount, and an increase in other general G&A expenses.”

From its results filing (SEC filing · Nov 6)

1 more sentence, for Pro members.

The numbers

Market value: $5.7B; today
Sales: $6.2M; up 184% on the year
Free cash flow: -$189M; last 12 months

3 more figures, for Pro members.

No analyst estimates on Breakaway: every figure here is filed.

The whole report on CGON: every line of its sales, every outlook beside the one it replaced, and the company's words, for Pro members.

Close after the report, last 3

+0.6%+3.4%+17.3%

May 8Aug 6Nov 6

Reported	When	Gap	Reaction	5 days
Nov 6, 2026Before open	Before open	+2.6%	+17.3%	not yet
Aug 6, 2026Before open	Before open	-0.8%	+3.4%	+6.3%
May 8, 2026Before open	Before open	-0.4%	+0.6%	+0.5%

CGON closed higher after 4 of its last 4 reports.

All 4 reports, and CGON's Quality Score going into each

CGON sales and profit by year

Sales and profit by year

Sales grew every year from 2023 to 2025, to $4M. It lost money in each of the three years.

CGON has 3 of 14 chart checks firing

Trend1 of 5 shown

MA FAN 21 EMA W.EMA HH/HL 52W HI

Volume1 of 3 shown

VOL VDU U/D VOL

Tight range1 of 3 shown

ATR SQZ SQUEEZE NR7

Buying1 of 3 shown

OBV+CLOSE HI SPRING

The other 10 checks on CGON, and all 14 on every stock.Get in free →

CGON RSI today: 60.4, above its 50-day and 200-day averages

Not scored

RSI 60.4, MACD above signal, above both averages. Not scored.13 readings

The deep dive on CGON

What it does and how it makes money4 findingsLicense And Collaboration Revenue made up 20% of its revenue in fiscal 2025 ($806K of $4.04M), against 100% in fiscal 2024; commercial and development revenue 80%.SEC filing · Feb 27, 2026
Where it stands3 findingsFor Pro members3 findings on where CGON stands: its cash, debt, and share count, for Pro members
What changed in its filings5 findings"On August 17, 2026, ANI filed a notice of appeal with the Delaware Supreme Court appealing (1) the Superior Court's granting of the Company's motion for summary judgment with respect to ANI’s request for a declaratory judgment to receive royalty payments from the potential sale of cretostimogene …" (10-Q for the quarter to Sep 30, 2026)SEC filing · Nov 6, 2026A new heading in its "Risk Factors" this year: "We acquired a controlling interest in Biovire, Inc., a contract manufacturing organization that provides our clinical supply and, if any of our product candidates are approved …" (10-K for fiscal 2025; not in fiscal 2024's)SEC filing · Feb 27, 2026, against the one of Mar 28, 2025
Who holds and trades it3 findingsFor Pro members3 findings on who holds and trades CGON, for Pro members
Against its closest peers4 peersShare count against a year before: CGON +16%, EXEL -8.1%, IOVA +25%, DNLI +9.3%.

12 more findings on CGON, each with its source, for Pro members.

CGON share count over time

Shares: 15.8% more than a year ago (to Sep 30).

Shares of CGON outstanding, as filed
Shares outstanding	As of
89.3M	Nov 4, 2026
88.6M	Aug 5, 2026
88.2M	May 6, 2026
84.4M	Feb 25, 2026

Offerings, shelves, and splits of CGON, from its filings
From its filings	Filed
Registered shares for a later sale (S-3ASR)	Mar 28, 2025
Raised $224M in a sale of shares, about 4% of its market value	Dec 13, 2024
Registered shares for sale (S-1)	Dec 11, 2024
Raised $380M in a sale of shares, about 7% of its market value	Jan 25, 2024

CGON insider trades

One insider bought $24.8M across 1 filing in the last 6 months. No open-⁠market sales on record. The newest:

BuyBrian Guan-Chyun Liu$24.8MDirectorat $66.87 on Jun 25, filed Jun 29

BuyBrian Guan-Chyun LiuDirector$24.8Mat $66.87 on Jun 25, filed Jun 29

CGON's officers and directors

Officers and directors with a Form 4 in the last 12 months.

Arthur KuanChief Executive Officer · no trades on file
Leonard E. PostDirector · 8 trades
James MulayDirector · 5 trades
Brian Guan-Chyun LiuDirector · 1 trade

See insider trades by person

Which ETFs hold CGON?

In ETFs: CGON is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.

About CG Oncology

CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing its product candidate, cretostimogene grenadenorepvec, for patients with bladder cancer. The company's candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.

142 employeesDallas, TXcgoncology.com

What CG Oncology says it competes with

“We face substantial competition from multiple sources, including large and specialty pharmaceutical and biotechnology companies, academic research institutions and governmental agencies and public and private research institutions.”

From its annual report, SEC filing · Feb 27, 2026

Here is what Pro members see.

The same page for Pro members, on Microsoft
Its Quality Score and rank, the line that drives it, and the live price.
The full chart
A year of candles to start, out to the whole history, with insider trades marked and the Quality Score under the price.
Every line of the score
Price action, the company, and signals, each with its points, on CGON and every other stock.
FDA dates, counted down
Each date in the company's words, its cash against the date, and an optional alert before it.
CEOs buying their own stock
Every CEO buy, biggest names first. Sort, filter, save the list, and set optional alerts.
Congress trades
A member's trades, newest first, each with its amount. Sort and filter the whole list.
14 chart checks, read for you
The ones firing on the stock, each in plain words, its rule a tap away.
Earnings, week by week
Who reports each day, and how each stock took its last four reports.
The market map
Every stock a box, colored by its Quality Score.
Themes, ranked live
Each theme's stocks ranked by Quality Score, live. Here, AI chips.
The top 10, every day
The ten highest Quality Scores at each close, kept day by day, week by week.
Optional alerts, your way
Pick a stock, a score, a price, a filing, or a whole scan. It tells you by push or email.
Your watchlist, scored
Your stocks by Quality Score, today's move, or name.
On your phone and your laptop
The same account and watchlist on both, each laid out for its screen.

Prices refresh every 2.5 seconds during market hours.
Optional alerts by push, email, or the bell.
Add it to your Home Screen and it opens like an app.

Pro members see every line of every stock's score.

What would turn CGON's score around: 9 things
7 more filings explained, a plain line each
Real-⁠time prices, no delay

BreakawayJun 29Brian Guan-Chyun Liu bought CGON$24.8M at $66.87, filed Jun 29

Alerts are optional.

See CGON's 14 chart checks

See it live, free until Thursday morning. No account. No card. Then keep going with a free account.

Straight AnswersStraight Answers

As of Nov 10, 2026: CGON's Quality Score is 4 (Below Average), #81 of 281 in Biotech. Insiders bought $24.8M in the last 6 months (Form 4).

What does CGON's Quality Score say?

CGON scores 4 today, which Breakaway calls Below Average. It is #81 of 281 in Biotech by Quality Score, with 3 of 14 chart checks firing. Up 17% on Nov 6 while the S&P 500 rose 0.3%. Shares: 15.8% more than a year ago (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.

What is CGON's Quality Score?

CGON scores 4 today, which Breakaway calls Below Average (0 to 5). That is #81 of 281 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind CGON's 4.

Are insiders buying CGON?

One insider bought $24.8M across 1 filing in the last 6 months. No open-⁠market sales on record. The newest is Brian Guan-⁠Chyun Liu, Director, who bought $24.8M on Jun 25.

Are the prices delayed?

Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.